Pantoprazole sodium hydrate - CAS# 164579-32-2 melatine (L(+)-Tartaric acid) A phase I/II clinical trial

A phase I/II clinical trial evaluating abiraterone in advanced breast cancer patients is also underway

24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2

15(10):1051-62

1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors

Pantoprazole sodium hydrate - CAS# 164579-32-2 melatine (L(+)-Tartaric acid) A phase I/II clinical trialPantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H+ K+ ATPase inhibitor with an IC50 of 6. 8 M. Pantoprazole sodium hydrate improves pH stability and has anti secretory, anti ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY 15142). Product information